Skip to main content
SpringerLink
Log in

NICE: pertuzumab not recommended for breast cancer

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • NICE. Long term benefits of breast cancer drug pertuzumab too uncertain says NICE in draft guidance. Media Release : 19 May 2016. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE: pertuzumab not recommended for breast cancer. PharmacoEcon Outcomes News 754, 36 (2016). https://doi.org/10.1007/s40274-016-3106-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3106-1

Search

Navigation